References
1. Kaplan JA: Leukemia in Children. Pediatr Rev 2019, 40(7):319-331.
2. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, Hunger SP, Devidas M, Children’s Oncology G: Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children’s Oncology Group Report. Leukemia 2010, 24(2):285-297.
3. Maloney KW, Devidas M, Wang C, Mattano LA, Friedmann AM, Buckley P, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA et al: Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0331. J Clin Oncol 2020, 38(6):602-612.
4. Pui CH, Mullighan CG, Evans WE, Relling MV: Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012, 120(6):1165-1174.
5. Surapolchai P, Anurathapan U, Sermcheep A, Pakakasama S, Sirachainan N, Songdej D, Pongpitcha P, Hongeng S: Long-Term Outcomes of Modified St Jude Children’s Research Hospital Total Therapy XIIIB and XV Protocols for Thai Children With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 2019, 19(8):497-505.
6. Attarbaschi A, Mann G, Zimmermann M, Bader P, Barisone E, Basso G, Biondi A, Cario G, Cazzaniga G, Colombini A et al: Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia 2020, 34(6):1694-1700.
7. Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE: Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol 2004, 83 Suppl 1:S124-126.
8. Quist-Paulsen P, Toft N, Heyman M, Abrahamsson J, Griškevičius L, Hallböök H, Jónsson ÓG, Palk K, Vaitkeviciene G, Vettenranta K et al: T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia 2020, 34(2):347-357.
9. Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S: Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 2013, 14(3):199-209.
10. Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Zheng HW, Davies SM et al: Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031. Leukemia 2014, 28(7):1467-1471.
11. Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C, Stary J, Felice MS, Magyarosy E, Conter V et al: Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005, 366(9486):635-642.
12. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Campana D, Kun LE, Jeha S et al: Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010, 24(2):371-382.
13. Campana D: Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr Opin Hematol 2012, 19(4):313-318.
14. Bader P, Salzmann-Manrique E, Balduzzi A, Dalle J-H, Woolfrey AE, Bar M, Verneris MR, Borowitz MJ, Shah NN, Gossai N et al: More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Advances 2019, 3(21):3393-3405.
15. Pui C-H, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M et al: Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. New England Journal of Medicine 2009, 360(26):2730-2741.
16. Yetgin S, Tuncer MA, Çetin M, Gümrük F, Yenicesu I, Tunç B, Öner AF, Toksoy H, Koç A, Aslan D et al: Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up. Leukemia 2003, 17(2):328-333.
17. Manji A, Lehrnbecher T, Dupuis LL, Beyene J, Sung L: A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Supportive Care in Cancer 2012, 20(10):2295-2304.
18. Petty LA, Sokol EA, Bartlett AH, McNeer JL, Alexander KA, Pisano J: Repeated Blood Cultures in Pediatric Febrile Neutropenia: Would Following the Guidelines Alter the Outcome? Pediatric Blood & Cancer 2016, 63(7):1244-1249.
19. Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H et al: Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol 2015, 16(4):465-474.
20. Gao YJ, Lu FJ, Wang HS: Treating childhood acute lymphoblastic leukemia in a developing country 1998-2003: the experience of a single children’s hospital in China. J Pediatr Hematol Oncol 2006, 28(12):798-802.
21. Howard SC, Pedrosa M, Lins M, Pedrosa A, Pui C-H, Ribeiro RC, Pedrosa F: Establishment of a Pediatric Oncology Program and Outcomes of Childhood Acute Lymphoblastic Leukemia in a Resource-Poor Area. JAMA 2004, 291(20):2471-2475.
22. Liang DC, Yang CP, Lin DT, Hung IJ, Lin KH, Chen JS, Hsiao CC, Chang TT, Peng CT, Lin MT et al: Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 2010, 24(2):397-405.
23. Gupta S, Yeh S, Martiniuk A, Lam CG, Chen HY, Liu YL, Tsimicalis A, Arora RS, Ribeiro RC: The magnitude and predictors of abandonment of therapy in paediatric acute leukaemia in middle-income countries: a systematic review and meta-analysis. Eur J Cancer 2013, 49(11):2555-2564.
24. Magrath I, Steliarova-Foucher E, Epelman S, Ribeiro R, Haraif M, Chi-Kong L, Rejin K: Improving cancer care for children and young people 2. Lancet Oncol 2013, 13:104-116.
25. Pui CH, Boyett JM, Relling MV, Harrison PL, Rivera GK, Behm FG, Sandlund JT, Ribeiro RC, Rubnitz JE, Gajjar A et al: Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 1999, 17(3):818-824.
26. Shuster JJ, Wacker P, Pullen J, Humbert J, Land VJ, Mahoney DH, Jr., Lauer S, Look AT, Borowitz MJ, Carroll AJ et al: Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 1998, 16(8):2854-2863.
27. Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM: Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. British journal of haematology 2009, 146(3):292-299.
28. Seif AE, Fisher BT, Li Y, Torp K, Rheam DP, Huang Y-SV, Harris T, Shah A, Hall M, Fieldston ES et al: Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatric Blood & Cancer 2014, 61(5):846-852.
29. Khan MI, Naseem L, Manzoor R, Yasmeen N: Mortality analysis in children during induction therapy for acute lymphoblastic leukemia. JIMDC 2017, 6(2):69-72.
30. Diba F, Karim MA, Soma SA, Chowdhury I, Mamun S, Mondal MNI: Immunophenotypic Pattern and Treatment Outcome after Completion of Induction Remission in Children with Acute Lymphoblastic Leukemia. Journal of Current and Advance Medical Research 2021, 8(1):59-64.
31. Lund B, Åsberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H, Söderhäll S, Jónsson ÓG, Lydersen S, Schmiegelow K et al: Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatric Blood & Cancer 2011, 56(4):551-559.
32. Kiem Hao T, Nhu Hiep P, Kim Hoa NT, Van Ha C: Causes of Death in Childhood Acute Lymphoblastic Leukemia at Hue Central Hospital for 10 Years (2008-2018). Global Pediatric Health 2020, 7:2333794X20901930.
33. Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE, on behalf of the Csg: Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia 2010, 24(2):298-308.
34. Gupta S, Antillon FA, Bonilla M, Fu L, Howard SC, Ribeiro RC, Sung L: Treatment-related mortality in children with acute lymphoblastic leukemia in Central America. Cancer 2011, 117(20):4788-4795.
35. Reiter A, Schrappe M, Ludwig W, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994, 84(9):3122-3133.
36. Koc A, Aycicek A, Ozdemir ZC, Soker M, Varma M: Outcome of modified St Jude total therapy 13A for childhood acute lymphoblastic leukemia in the southeast region of Turkey. Journal of pediatric hematology/oncology 2013, 35(1):36-41.
37. Öztürk AP, Koç B, Zülfikar B: Acute Complications and Survival Analysis of Childhood Acute Lymphoblastic Leukemia: A 15-year Experience. Clinical Lymphoma Myeloma and Leukemia 2021, 21(1):e39-e47.
38. Conter V, Aricò M, Basso G, Biondi A, Barisone E, Messina C, Parasole R, De Rossi G, Locatelli F, Pession A et al: Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010, 24(2):255-264.
39. Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig W-D, Ritter J, Harbott J, Mann G et al: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2009, 24:265-284.
40. Harms DrO, Göbel U, Spaar HJ, Graubner UB, Jorch N, Gutjahr P, Janka-Schaub GE, Group ftCS: Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 2003, 102(8):2736-2740.
41. Kamps WA, van der Pal-de Bruin KM, Veerman AJP, Fiocco M, Bierings M, Pieters R: Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 2010, 24(2):309-319.
42. Vrooman LM, Stevenson KE, Supko JG, O’Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL et al: Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study–Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013, 31(9):1202-1210.
43. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G, Mellander L, Mäkipernaa A, Nygaard R, Saarinen-Pihkala U: Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia 2000, 14(12):2267-2275.
44. Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, Klausen TW, Jónsson Ó, Palk K, Pruunsild K et al: Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia 2018, 32(3):606-615.
45. Pui CH, Pei D, Campana D, Cheng C, Sandlund JT, Bowman WP, Hudson MM, Ribeiro RC, Raimondi SC, Jeha S et al: A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia 2014, 28(12):2336-2343.
46. Hough R, Rowntree C, Goulden N, Mitchell C, Moorman A, Wade R, Vora A: Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. Br J Haematol 2016, 172(3):439-451.